Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sarracenia purpurea extract is a botanical preparation derived from the purple pitcher plant, Sarracenia purpurea, native to North America. It has a long history of traditional use, particularly among indigenous communities, for the management of symptoms associated with diabetes, pain, and viral infections. The leaf extract has demonstrated cytoprotective and anti-diabetic activity in vitro, chiefly mediated by active constituents such as hyperoside (quercetin-3-O-galactoside) and morroniside, which may protect cells from glucose toxicity and diabetic neuropathy. The root extract is used in topical pain relief preparations (e.g., Sarapin) and has shown potential antioxidant, anticancer, and antibacterial properties, notably inhibiting targets like human dihydroorotase. Sarracenia purpurea extracts display antiviral properties against herpes simplex virus type 1 (HSV-1) and poxvirus, through dual mechanisms: direct inhibition of virus attachment/entry and inhibition of viral gene expression. The complete spectrum of active compounds remains unidentified, and further studies are required to confirm the clinical efficacy and precise mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sarracenia purpurea extract.